The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants

Rothenberger, S; Hurdiss, DL; Walser, M; Malvezzi, F; Mayor, J; Ryter, S; Moreno, H; Liechti, N; Bosshart, A; Iss, C; Calabro, V; Cornelius, A; Hospodarsch, T; Neculcea, A; Looser, T; Schlegel, A; Fontaine, S; Villemagne, D; Paladino, M; Schiegg, D; Mangold, S; Reichen, C; Radom, F; Kaufmann, Y; Schaible, D; Schlegel, I; Zitt, C; Sigrist, G; Straumann, M; Wolter, J; Comby, M; Sacarcelik, F; Drulyte, I; Lyoo, H; Wang, CY; Li, WT; Du, WJ; Binz, HK; Herrup, R; Lusvarghi, S; Neerukonda, SN; Vassell, R; Wang, W; Adler, JM; Eschke, K; Nascimento, M; Abdelgawad, A; Gruber, AD; Bushe, J; Kershaw, O; Knutson, CG; Balavenkatraman, KK; Ramanathan, K; Wyler, E; Alves, LGT; Lewis, S; Watson, R; Haeuptle, MA; Zurcher, A; Dawson, KM; Steiner, D; Weiss, CD; Amstutz, P; van Kuppeveld, FJM; Stumpp, MT; Bosch, BJ; Engler, O; Trimpert, J

Stumpp, MT (通讯作者),Mol Partners AG, Zurich, Switzerland.

NATURE BIOTECHNOLOGY, 2022; 40 (12):

Abstract

Multiple variants of SARS-CoV-2 are inhibited by a trispecific DARPin. The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) v......

Full Text Link